Search Results
Your search for ,itS matches 8694 pages
Showing 151 - 200Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer
In patients with high-risk non–muscle-invasive bladder cancer, the addition of 1 year of the PD-L1 inhibitor durvalumab to standard induction and maintenance bacillus Calmette-Guérin (BCG) infusions led to a statistically significant and clinically meaningful improvement in disease-free survival...
Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC
In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizumab-jsgr plus chemotherapy, a 40% reduction in risk as first-line treatment of advanced squamous...
European Society for Medical Oncology Congress 2025 Meeting Highlights
The European Society for Medical Oncology (ESMO) Congress 2025 in Berlin featured many important trials with the potential to significantly influence clinical practice and improve outcomes for patients with multiple tumor types. These studies highlighted the benefits of novel treatment combination...
HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings
Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative setting after having shown benefit in metastatic disease in multiple previous trials. The new...
Large AI Breast Cancer Screening Trial Increases Detection Rate by 20%
Using an artificial intelligence (AI)–integrated workflow, DeepHealth, in computer-aided detection of breast cancer from digital breast tomosynthesis exams found 21.6% more cases than the usual standard of care, according to findings from the AI-Supported Safeguard Review Evaluation (ASSURE) study...
Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With Acute Myeloid Leukemia
“Pretreatment geriatric assessment in older adults with acute myeloid leukemia is feasible, can identify several functional impairments, and [can] guide the selection of treatment intensity,” resulting in low rates of early mortality, according to Vijaya R. Bhatt, MBBS, MS, of the University of...
ASTRO Experts Comment on the Results of the SUPREMO Trial
A large international study published by Kunkler et al in The New England Journal of Medicine examined whether chest wall radiation therapy after mastectomy improves survival for patients with early-stage breast cancer. The study, known as the SUPREMO trial, found no overall survival difference...
Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women?
Known as “the silent killer” due to its lack of symptoms and reliable screening tests, ovarian cancer remains one of the deadliest gynecologic cancers, claiming more than 12,000 lives annually. At a recent meeting, experts said that performing a single preventive procedure within general surgery...
New Study Explores Why Male Patients With AML May Have Worse Outcomes
New research has ruled out hormone signaling as the reason why men with acute myeloid leukemia (AML) tend to have poorer outcomes than women, even when treated with the same intensive chemotherapy—a finding that helps refine future research and could influence clinical trial design. The...
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated NSCLC After Tyrosine Kinase Inhibitor Failure
Sacituzumab tirumotecan, a novel TROP2 antibody-drug conjugate, was found to significantly improve both progression-free and overall survival compared with platinum-based chemotherapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC) who had experienced disease progression following...
MD Anderson Launches $2.5 Billion Philanthropic Campaign: Only Possible Here, The Campaign to End Cancer
The University of Texas MD Anderson Cancer Center has launched its historic $2.5 billion comprehensive philanthropic campaign, Only Possible Here, The Campaign to End Cancer. The campaign represents the largest fundraising effort in MD Anderson's 84-year history, bringing together philanthropic...
Pancreatic Cancer: Mild Duct Dilation May Serve as Early Indicator in High-Risk Patients
Mild dilation of the main pancreatic duct without an apparent obstructing mass may be an independent risk factor for neoplastic progression to pancreatic cancer in high-risk individuals, according to findings from an analysis published in Gastro Hep Advances. “We are identifying pancreas duct...
Longtime FDA Innovator Appointed as Director of CDER
The U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) announced that Richard Pazdur, MD, has been appointed Director of the Center for Drug Evaluation and Research (CDER). Dr. Pazdur is a 26-year veteran of the FDA and the Founding Director of its...
Immunotherapy Combination Active in Patients With Large B-Cell Lymphoma Who Are Not Eligible for Autologous Stem Cell Transplant
In the global phase III SUNMO trial, the combination of a bispecific antibody and an antibody-drug conjugate was compared with rituximab plus gemcitabine and oxaliplatin (GemOx) in the treatment of patients with relapsed or refractory large B-cell lymphoma (LBCL) who were ineligible for autologous...
ASTRO Announces New President-Elect, Officers to Board of Directors
The members of the American Society for Radiation Oncology (ASTRO) recently elected four new officers to ASTRO’s Board of Directors: Catheryn M. Yashar, MD, FASTRO, President-Elect; Jonathan Strauss, MD, MBA, Secretary/Treasurer-Elect; Anita Mahajan, MD, FASTRO, Health Policy Council Vice Chair;...
Intensity-Modulated Radiation Therapy vs Proton Therapy for Oropharyngeal Cancer
The phase III TORPEdO trial reported no meaningful differences between intensity-modulated radiation therapy (IMRT) and proton beam therapy at 1 year in terms of patient-reported quality of life, swallowing function, or feeding tube dependence for individuals with locally advanced oropharyngeal...
Extended ERSPC Analysis Demonstrates Long-Term Mortality Benefit of PSA Screening for Prostate Cancer
In an updated analysis published in The New England Journal of Medicine, Roobol et al reported long-term findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC) on the survival benefit of prostate-specific antigen (PSA) screening. The study, which was initiated in 1993, ...
New Report: Lung Cancer Advancements Are Saving More Lives Than Ever, but Funding Cuts May Hinder Progress
The American Lung Association has released its 2025 “State of Lung Cancer” report, which reveals great strides in efforts to end lung cancer—the leading cause of cancer-related deaths in the United States. This year, nearly 227,000 people in the United States will be diagnosed with lung cancer....
Diminishing the National Cancer Institute Threatens Americans
In an effort to reduce the size of government, the current administration has proposed an across the board 37% reduction1 in funding for the National Cancer Institute (NCI). This will result in approval of only 4% of applications2 from scientists at universities and cancer centers, with 96% of all ...
Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up of ZUMA-5
As reported in the Journal of Clinical Oncology by Neelapu et al, the 5-year follow-up of the phase II ZUMA-5 trial has shown sustained responses with axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Study Details In the single-arm,...
Reflections of a Medical Oncologist: Empathy Matters in Caring for Patients With Cancer
“Someday you will be a doctor, Fazlur, and help people,” were the prophetic words of a mother to her son and the driving force behind the early quest of Fazlur Rahman, MD, to become a physician. Born and raised in what is now Bangladesh, he experienced the death of his mother at the young age of ...
My 50 Years in Lymphoma: Lessons Learned?
In the 50 years now since my fellowship training, there have been major advances in the diagnosis, staging, prognostic scoring, treatment, and response assessment of lymphomas. To conjure up the future, we must first appreciate the present by understanding how it arose from the past.1 So, a trip in ...
Preneoplastic and Neoplastic Small Lymphocytic Proliferations
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the key epidemiologic, pathologic, diagnostic, and prognostic aspects of chronic...
Elironrasib Active in KRAS G12C–Resistant NSCLC
Elironrasib, a novel RAS G12C–selective tri-complex inhibitor, demonstrated initial clinical activity and a differentiated safety profile in heavily pretreated patients with non–small cell lung cancer (NSCLC) and KRAS G12C mutations, according to findings from a phase I trial presented at the 2025...
ASTRO Announces 2025 Awards and Research Grants
The American Society for Radiation Oncology (ASTRO) recognized the recipients of the 2025 Gold Medal awards and other high-profile honors during its recent Annual Meeting. ASTRO also recognized the recipients of its 2025 research grants and fellowships, including awards cosponsored by patient,...
HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings
Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative setting after having shown benefit in metastatic disease in multiple previous trials. The new...
How the Proliferation of Fraudulent Scientific Papers Is Threatening the Integrity of Cancer Research
There is a perception among many scientists that scientific fraud is a rare occurrence, resulting from the actions of a few isolated bad actors. However, an extensive investigation by Reese A.K. Richardson, PhD, postdoctoral fellow at the Center for Science of Science and Innovation, Kellogg School ...
Biomarker-Driven Apalutamide Therapy for Patients With Recurrent Prostate Cancer
Use of PAM50 subtyping allowed clinicians to determine which patients with recurrent prostate cancer were most likely to benefit from the addition of apalutamide hormonal therapy to salvage radiotherapy, according to findings from the phase II BALANCE trial (NRG GU006). These results were presented ...
Medicine Is in the Genes of Neelima Denduluri, MD, FASCO, a Third-Generation Clinician
Growing up in Draksharamam, a small village in India, Neelima Denduluri, MD, FASCO, was attracted to the field of medicine after witnessing her grandfather, a general practitioner in the village, care for patients so poor he often provided medical services at no cost. Although Dr. Denduluri’s...
How a $2 Billion Gift to the Knight Cancer Institute May Accelerate Cancer Advances and Streamline Care for Patients
On August 14, 2025, Oregon Health & Science University (OHSU) announced that Phil Knight, a cofounder of Nike, and his wife, Penny, donated $2 billion to the OHSU Knight Cancer Institute. The record-setting gift is the largest single donation ever made to a U.S. university, college, or academic ...
AGA Issues New Guideline Urging Risk-Based Surveillance in Barrett’s Esophagus
The American Gastroenterological Association (AGA) has released an updated clinical practice guideline on surveillance of Barrett’s esophagus, the only known precursor to esophageal adenocarcinoma. The new guideline, which was published in Gastroenterology, emphasizes risk-based, individualized...
New Guideline Reflects the Latest Evidence in Support of Postmastectomy Radiation Therapy for Patients With Breast Cancer
A joint task force composed of experts from the American Society of Radiation Oncology (ASTRO), ASCO, and the Society of Surgical Oncology (SSO) has released new guidance for postmastectomy radiation therapy (PMRT) for patients with breast cancer.1 This guideline—which is intended to replace the...
How Embedding an Algorithm-Based Referral System Into Electronic Health Records Is Increasing Access to Palliative Care
Despite numerous studies showing the benefits of integrating palliative care in both the early- and advanced-stage cancer settings,1 palliative care remains underutilized for most patients with cancer. A recent study by the American Cancer Society found that only 10% of Medicare beneficiaries with...
ESMO Publishes Guidance on Large Language Model Use for Oncology Practice
The European Society for Medical Oncology (ESMO) has released its first set of recommendations for the use of artificial intelligence (AI) large language models in oncology practice, called the ESMO Guidance on the Use of Large Language Models in Clinical Practice (ELCAP). The guidance was...
ADC Improves Outcomes for Patients With Advanced TNBC Ineligible for Immunotherapy
Patients with an aggressive type of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody-drug conjugate (ADC) sacituzumab govitecan-hziy compared with standard chemotherapy. These...
Belzutifan Achieves Durable Responses Without Surgery in Advanced Pheochromocytoma/Paraganglioma
Belzutifan induced durable responses without surgery in patients with advanced pheochromocytoma or paraganglioma and demonstrated manageable safety in the phase II LITESPARK-015 trial, according to findings presented during the European Society for Medical Oncology (ESMO) Congress 2025 (Abstract...
Metastatic ER-Positive, HER2-Negative Breast Cancer: Novel Treatment Combination Improves Progression-Free Survival
Patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full...
New Leadership Elected to the American Society of Hematology
The American Society of Hematology (ASH) announced the election of three new members to its Executive Committee for terms starting after the 2025 ASH Annual Meeting, taking place December 6 to 9 in Orlando, Florida. Alison Loren, MD, MSCE, will serve a 1-year term as Vice President followed by...
New AACI President-Elect Selected; Two Cancer Center Leaders Join Board
Cornelia Ulrich, MS, PhD, has been elected by the members of the Association of American Cancer Institutes (AACI) to serve as Vice President/President-Elect of AACI’s Board of Directors. Dr. Ulrich is Chief Scientific Officer and Executive Director of the Comprehensive Cancer Center at Huntsman...
Alcohol and Cancer Risk: Is a Drop Too Much?
In 2022, Congress requested a scientific review from the National Academies of Sciences, Engineering, and Medicine (NASEM) to study the associated risks of cancer and other health conditions and the use of alcohol. The concern was that the health risks associated with low-to-moderate consumption of ...
EHA Publishes Guidelines for LBCL and Multiple Myeloma
The European Hematology Association (EHA) has published two new sets of clinical practice guidelines, including its first dedicated guidelines for large B-cell lymphoma (LBCL), which was published in HemaSphere, as well as an updated set of guidelines in collaboration with the European Myeloma...
Fertility-Sparing Surgery vs Hysterectomy for Early-Stage Cervical Cancer: Comparable Survival Rates but Higher Recurrence Risk
In a nationwide study published in JCO Oncology Practice, Wolswinkel et al evaluated the long-term oncologic safety of fertility-sparing surgery (FSS) compared with hysterectomy in women with early-stage cervical cancer. The study—one of the largest of its kind—addresses a critical question for...
Creatine
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus...
Incidence of Invasive Lobular Carcinoma Rising Faster Than Other Breast Cancers
Incidence rates for invasive lobular carcinoma have increased more drastically than all other breast cancers combined between 2012 and 2021, according to findings from the American Cancer Society’s Lobular Breast Cancer Statistics 2025 report, published in Cancer. “Although lobular breast cancer...
Advanced Biliary Tract Cancer: Adding a Polymeric Micellar Paclitaxel to Gemcitabine Plus Cisplatin
Based on the results of the multicenter phase III NEXT trial published by Jeong et al in JAMA Network Open, the addition of a polymeric micellar paclitaxel to standard chemotherapy with gemcitabine plus cisplatin did not improve overall survival in patients with previously untreated advanced...
John L. Cameron, MD, FACS, Receives Wangensteen Scientific Forum Award
John L. Cameron, MD, FACS, a surgeon who radically improved the mortality rates of the Whipple procedure, was honored with the American College of Surgeons (ACS) Owen H. Wangensteen Scientific Forum Award at the ACS Clinical Congress 2025 in Chicago. The award recognizes a surgeon who exemplifies...
Considerations on Cancer Drug Development
In the 1940s, the first drugs proven to cause objective responses in human cancers were developed. Mechlorethamine was discovered as a possible treatment of lymphoid cancers after autopsies on military personnel exposed to mustard gas found destruction of lymphatic tissue and bone marrow....
Inflammatory Activity and Cancer-Related Fatigue in Early Breast Cancer
Research published in Cancer revealed that inflammatory responses may be tied to cancer-related fatigue and certain inflammatory activities may lead to distinct dimensions of fatigue in women with early-stage breast cancer. “Our findings indicate that inflammation plays a role in some aspects of...
Improved Outcomes Reported With Second-Line Regimen of Ivonescimab Plus Chemotherapy in NSCLC
In the phase III HARMONi trial, when ivonescimab was given with carboplatin plus pemetrexed, vs the chemotherapy regimen alone, after a third-generation tyrosine kinase inhibitor, patients with EGFR-mutated non–small cell lung cancer (NSCLC) had a significant delay in disease progression.1...
Network of Cancer Drug Repositories Improves Access to Treatment, Reduces Waste
A new study found that implementing a network of cancer drug repositories (CDRs) improved access to cancer medications and eliminated unnecessary medication waste by allowing people to donate unopened or unused medications that would otherwise be wasted. This resulted in patients with cancer...
